[1. Brites FD, Bonavita CD, Cloes M, Yael M. VLDL Compositional changes and plasma levels of triglycerides and high density lipoproteins. Clinica Chimica Acta. 1998;269:107 124.10.1016/S0009-8981(97)00193-9]Search in Google Scholar
[2. Goldberg DM. The Plasma Lipoprotein system. Clinical Biochemistry Reviews. 1981;2:341–353.]Search in Google Scholar
[3. Burtis CA, Ashwood ER, editors. Tietz Fundamentals of Clinical Chemistry. 4th ed. Philadelphia, Pa: WB Sunders; 1996. Lipids, Apolipoproteins and Lipoproteins; pp. 375–386.]Search in Google Scholar
[4. Cummings KC. Lipid and Cardiac Risk profiles. Clinical Chemistry. 2003;47:407–409.]Search in Google Scholar
[5. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart study. Can J Cardiol. 1988;4:5–10]Search in Google Scholar
[6. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor to cardio vascular disease independent of high density lipoprotein cholesterol level: a meta analysis of population based prospective studies. J Cardiovasc Risk. 1996;3:213–219.]Search in Google Scholar
[7. Guerin M, Legoff W, Lassel TS, VanTol A, Steiner G, Chapman MJ. Proatherogenic role of elevated CE transfer from HDL to VLDL and dense LDL in type 2 diabetics. Arterioscler Thromb Vasc Biol. 2001;21:282–287.10.1161/01.ATV.21.2.282]Open DOISearch in Google Scholar
[8. Gaziano JM, Henne kens CH, O’Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high density lipo-protein, and risk of myocardial infarction. Circulation. 1997;96:2520–2525.10.1161/01.CIR.96.8.2520]Search in Google Scholar
[9. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apo B-lipoprotein-depleted plasma. (FERHDL) Clin Biochem. 2001;34:583–588.10.1016/S0009-9120(01)00263-6]Open DOISearch in Google Scholar
[10. Jakubowski H. Proofreading in vivo. Editing of homo-cysteine by aminoacyl-tRNA synthetases in Escherichia coli. J Biol Chem. 1995;270:17672–17673.]Search in Google Scholar
[11. Jakubowski H. Metabolism of homocysteine thiolac-tone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem. 1997;272:1935–1942.10.1016/S0021-9258(19)67504-6]Search in Google Scholar
[12. Jakubowski H. Synthesis of homocysteine thiolactone in normal and malignant cells. In: Rosenberg IH, Graham I, Ueland PM, Refsum H, editors. Homocysteine metabolism: from basic science to clinical medicine. Norwell: Kluwer Academic Publishers; 1997. pp. 157–165.10.1007/978-1-4615-5771-5_22]Search in Google Scholar
[13. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. Faseb J. 1999;13:2277–2283.1059387510.1096/fasebj.13.15.2277]Search in Google Scholar
[14. Jakubowski H. Calcium-dependent human serum homo-cysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem. 2000;275:3957–3962. doi: 10.1074/jbc.275.6.3957.10.1074/jbc.275.6.3957]Open DOISearch in Google Scholar
[15. Jakubowski H. The determination of homocysteinethiolactone in biological samples. Anal Biochem. 2002;308:112–119. doi: 10.1016/S0003-2697(02)00224-5.10.1016/S0003-2697(02)00224-5]Open DOISearch in Google Scholar
[16. Eriksson M. [Statins have other beneficial properties besides their cholesterol lowering effect]. Lakartidningen. 1998 Aug 26;95(35):3670-2. Review. Swedish. PubMed PMID: 9748780]Search in Google Scholar
[17. Demacher M, Hijamaus A. A study of the use of polyethylene glycol in estimating cholesterol. Clin Chem. 1980; 26:1775.10.1093/clinchem/26.13.1775]Search in Google Scholar
[18. Foster L, Dunn R. Stable reagens for the determination os serum triglycerides by a colorimetric Hantzch condensation method. J Clin Chem 1973; 19:338.10.1093/clinchem/19.3.338]Search in Google Scholar
[19. Roberts WC. The Friedewald-Levy-Fredrickson formula for calculating low-density lipoprotein cholesterol, the basis for lipid-lowering therapy. Am J Cardiol. 1988;62:345–6.10.1016/0002-9149(88)90248-2]Open DOISearch in Google Scholar
[20. Zlatkis A, Zak B, Boyle A. A new method for the direct determination of cholesterol. J lab Clin Med. 1953;41:486–486]Search in Google Scholar
[21. Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, et al. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Medical Journal of the Islamic Republic of Iran. 2015;29:240.]Search in Google Scholar
[22. Brunt EM, Tiniakos DG. Alcoholic and nonalcoholic fatty liver disease. In: Odze RD, Goldblum JR, eds, editors. Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas. 2nd ed. Philadelphia: Elsevier; 2009. pp. 1007–101410.1016/B978-141604059-0.50044-8]Search in Google Scholar
[23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.10.1002/hep.2070115915461]Open DOISearch in Google Scholar
[24. Nikolic T, Zivkovic V, Srejovic I, Stojic I, Jeremic N, Jeremic J, Radonjic K, Stankovic S, Obrenovic R, Djuric D, Jakovljevic V. Effects of atorvastatin and simvastatin on oxidative stress in diet-induced hyperhomocysteinemia in Wistar albino rats: a comparative study. Mol Cell Biochem. 2017 Jun 15. doi: 10.1007/s11010-017-3099-5.10.1007/s11010-017-3099-528620818]Open DOISearch in Google Scholar
[25. Brown DJ. New guidelines for low-density lipoprotein levels fron the National Cholesterol Education Program (NCEP): a 2004 update. Prog Cardiovasc Nurs. 2004 Fall;19(4):165. PubMed PMID: 15539979.10.1111/j.0889-7204.2003.02910.x15539979]Search in Google Scholar
[26. King A. Cardioprotective effects of HDL cholesterol called into question. Nature Reviews Cardiology. 2012;9 [PubMed]10.1038/nrcardio.2012.8022665321]Search in Google Scholar
[27. Rekhter MD. How to evaluate plaque vulnerability in animal models of atherosclerosis? Cardiovascular research. 2002;54:36–41.]Search in Google Scholar
[28. Bhandari U, Pathan RA, Kumar V, Khanna N. Ameliorative role of atorvastatin on methionine-induced hyperhomcysteinemia and hematological changes in albino rats. Indian J Exp Biol. 2011: 132-9.]Search in Google Scholar
[29. Matté C, Stefanello FM, Mackedanz V, Pederzolli CD, Lamers ML, Dutra-Filho CS, Dos Santos MF, Wyse AT. Homocysteine induces oxidative stress, inflammatory infiltration, fibrosis and reduces glycogen/glycoprotein content in liver of rats. Int J Dev Neurosci. 2009; 27(4):337-44. 7.10.1016/j.ijdevneu.2009.03.00519460627]Open DOISearch in Google Scholar
[30. Zhang R, Ma J, Xia M, Zhu H, Ling WH. Mild hyperhomocysteinemia Induced by feeding Rats Diets Rich in Methionine or Deficient in Folate Promotes Early Atherosclerotic Inflamammatory Processes. J Nutr. 2004: 825-30.10.1093/jn/134.4.82515051832]Open DOISearch in Google Scholar
[31. Ankur Rohilla, M. U. Khan, Razia Khanam. Cardioprotective potential of simvastatin in the hyperhomocysteinemic rat heart. J Adv Pharm Technol Res. 2012; 3(3): 193–198.10.4103/2231-4040.101018345945023057007]Open DOISearch in Google Scholar
[32. Rohilla A, Ahmad A, Khan MU, Khanam R. A comparative study on the cardioprotective potential of atorvastatin and simvastatin in hyperhomocysteinemic rat hearts. Eur J Pharmacol. 2015;764:48-54.10.1016/j.ejphar.2015.06.045]Search in Google Scholar
[33. Olszewski AJ, McCully KS. Homocysteine content of lipoproteins in hypercholesterolemia. Atherosclerosis. 1991 May;88(1):61-8. PubMed PMID: 1878010.10.1016/0021-9150(91)90257-4]Search in Google Scholar
[34. Malik J, Melenovsky V, Wichterle D et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidemia (fenofibrate versus atorvastatin trial-FAT). Cardiovasc Res 2001: 290-8. 12.10.1016/S0008-6363(01)00382-011684077]Open DOISearch in Google Scholar
[35. Luftjohann D, Sigit IJ, Locatelli S, Bergmann VK. High-dose simvastatin (80mg/day) decreases plasma concentrations of total homocysteine in patients with hyper-cholesterolemia. Atherosclerosis. 2001: 265-6.10.1016/S0021-9150(00)00735-8]Open DOISearch in Google Scholar